Skip to main content

Market Overview

Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China

  • Karyopharm Therapeutics Inc's (NASDAQ: KPTI) collaborating partner Antengene Corporation Limited has received priority review from China's National Medical Products Administration (NMPA) for ATG-010 (selinexor, XPOVIO). It is a first-in-class selective inhibitor of nuclear export (SINE) compound to treat patients with relapsed/refractory multiple myeloma (rrMM).
  • The FDA has approved ATG-010 (selinexor) for three indications within 18 months, including relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma.
  • Selinexor is also being evaluated in the Phase 3 SIENDO trial in patients with endometrial cancer. Topline data expected in the second half of 2021.
  • Price Action: KPTI closed 2.2% lower at $14.59 on Tuesday.

Related Articles (KPTI)

View Comments and Join the Discussion!

Posted-In: multiple myeloma National Medical Products AdministrationBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at